Synthetic or natural indirect and synthetic direct factor Xa inhibitors with specific actions on only factor Xa are currently in clinical development. The aim of these compounds is to improve ... have to be administered…
venous thromboembolic disorders. The recently introduced novel oral anticoagulants target a single coagulation factor (factor Xa or thrombin) and address several of the limitations associated with traditional agents…
conformational changes are known to be key characteristic for the function of many proteins. Factor Xa is a serine protease which activates thrombin and plays a significant role in blood ... coagulation pathway…
that particular context, SAR107375 is a novel oral and intravenous anticoagulant, inhibiting both factors Xa and thrombin activities. Despite important efforts in various research laboratories, it remained very…
Direct factor Xa inhibitors are being used clinically. Clinical trials have shown promise for these compounds as substitutes for the currently administered vitamin K antagonists or low molecular weight heparin…
Factor Xa inhibitors are approved for the prevention of clot formation in non-valvular atrial fibrillation and for treating deep venous thromboembolism and pulmonary embolism. This class of medications ... liver injury…
LMWH administration in sheep at high risk of thromboembolic events. Target was an anti-factor-Xa (AFXa) level of 0.6 to 0.8 units known from human studies to be preventive ... monitor the response over 24 hours. The…
Rivaroxaban is a direct factor Xa inhibitor that can be administered orally for thromboprophylaxis in orthopedic patients undergoing hip or knee arthroplasty. The new drug is well tolerated with
coagulopathy in patients with intracranial hemorrhage while on vitamin K antagonists (VKA) and factor Xa inhibitors. Evaluation in a ‘real world’ population has not been performed. Material and methods: Retrospective…
Apixaban is a new oral selective factor Xa inhibitor. Its efficacy and safety are being investigated in a large clinical development program across various indications in venous and arterial thrombotic
laboratory tests are available; the Activated Partial Thromboplastin Time (aPTT) and the Anti-Factor Xa Assay. The aPTT has been the gold standard for monitoring IV heparin for more than ... cases, as the patient is…
this manuscript, I will focus on recent studies regarding: The effects of thrombin, factor Xa, and its inhibitors on tissue inflammation and fibrosis. The beneficial effects of thrombin inhibitors
easy to use. Edoxaban is a novel, oral, once daily, direct and reversible factor Xa inhibitor. It acts by dose-dependent anticoagulation effect and the safety and tolerability of this
recently discovered anticoagulant effect of acylcarnitines. Our studies show that acylcarnitines inhibit factor Xa-initiated clotting. Inhibition of factor Xa by acylcarnitines is greater for longer acyl chain lengths…
recently discovered anticoagulant effect of acylcarnitines. Our studies show that acylcarnitines inhibit factor Xa-initiated clotting. Inhibition of factor Xa by acylcarnitines is greater for longer acyl chain lengths…
Rivaroxaban is a potent, direct oral Factor Xa inhibitor with high oral bioavailability, predictable pharmacokinetics (PK), and a rapid onset and offset of action. Inhibiting Factor Xa blocks thrombin generation
these bioactive substances. They are proteinase inhibitors: bdellins, hirustasin, tryptase inhibitor, eglins, inhibitor of factor Xa, hirudin, inhibitor of carboxypeptidase, decorsin, gelin, and inhibitor of complement…
anticoagulant classes (vitamin K antagonists, including brodifacoum and warfarin, heparin, direct thrombin inhibitor and factor Xa inhibitor). Free hemoglobin concentration was measured in the brain. Results: Vitamin K…
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.